Cost-Effectiveness Analyses of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Diseases in Patients With Rheumatoid Arthritis: Three Approaches with a Cohort Simulation and Real-World Data.
Masataka KuwanaNaoto TamuraShinsuke YasudaKeishi FujioAyako ShojiHiroko YamaguchiKatsuhiko IwasakiMisako MakishimaYuichi KawataKatsuhisa YamashitaAtaru IgarashiPublished in: Modern rheumatology (2022)
The b/tsDMARDs with lower prices showed higher cost-effectiveness.